Neural Therapeutics Cash Flow Statement

Financials in millions CAD. Fiscal year is August - July.

Millions CAD. Fiscal year is Aug - Jul.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Oct '25 Oct 31, 2025	Jul '25 Jul 31, 2025	Jul '24 Jul 31, 2024	Jul '23 Jul 31, 2023	Jul '22 Jul 31, 2022
Net Income	-0.99	-1.03	-0.67	-1.08	-1.82
Stock-Based Compensation	0.41	0.41	-	-	-
Other Operating Activities	0.11	0.12	0.05	-0.01	1.08
Change in Accounts Payable	-0.17	-0.06	0.02	0.42	0.22
Change in Other Net Operating Assets	0.29	0.25	0.28	0.14	-0.08
Operating Cash Flow	-0.36	-0.32	-0.32	-0.53	-0.6
Short-Term Debt Issued	-	-	0.01	-	0.23
Total Debt Issued	-	-	0.01	-	0.23
Short-Term Debt Repaid	-	-0.01	-	-	-
Total Debt Repaid	-0.01	-0.01	-	-	-
Net Debt Issued (Repaid)	-0.01	-0.01	0.01	-	0.23
Issuance of Common Stock	0.47	0.47	0.11	0.43	0.79
Other Financing Activities	-0.04	-0.04	-0.01	-	-0.04
Financing Cash Flow	0.41	0.41	0.11	0.43	0.97
Net Cash Flow	0.05	0.1	-0.21	-0.1	0.37
Levered Free Cash Flow	-0.39	-0.32	-0.54	-0.74	-
Unlevered Free Cash Flow	-0.39	-0.32	-0.54	-0.74	-
Change in Working Capital	0.12	0.18	0.3	0.56	0.14

Source: S&P Global Market Intelligence. Standard template. Financial Sources.